Generic Wegovy and Ozempic Could Cost as Little as $3 a Month, Expanding Access
Generic versions of Novo Nordisk’s blockbuster medications Wegovy and Ozempic could turn into available for as little as $3 per person per month, potentially dramatically increasing access to these drugs, particularly in low- and middle-income countries. This shift is anticipated as patents for semaglutide, the active ingredient in both drugs, begin to expire this year.
Patent Expiration and Generic Production
Patents for semaglutide are expiring starting later in March 2026 in India, China, Canada, Brazil, and Turkey, along with three other countries later this year. This expiration is expected to pave the way for the mass production and distribution of generic versions of the medications. India, with its robust generic pharmaceutical industry, is poised to be a key player in supplying these more affordable alternatives.
Cost Analysis of Generic Semaglutide
Researchers estimate that a generic version of semaglutide could be manufactured for between $28 and $140 per person annually. This translates to a monthly cost of approximately $2.33 to $11.67, significantly lower than the current list prices of Wegovy and Ozempic.
Current Costs of Wegovy and Ozempic
As of February 2026, Wegovy and Ozempic both have list prices around $1,350 per month, while Ozempic and Rybelsus have list prices around $1,027 per month. However, insured patients may pay as little as $25 a month depending on their coverage. Novo Nordisk announced in February 2026 plans to slash the list prices of these drugs by up to 50% starting in January 2027, bringing the cost down to $675 per month.
Impact on Access and Competition
The availability of generic semaglutide is expected to increase access to these medications for individuals with diabetes and obesity, particularly those with high-deductible health plans or coinsurance benefit designs. This move also comes as Novo Nordisk faces increasing competition from Eli Lilly, which manufactures Zepbound and Mounjaro, in the GLP-1 market.
Wegovy Pill Availability
Wegovy is now available as a once-daily pill, in addition to the injectable form, making it the only semaglutide tablet FDA-approved for weight loss in adults.
Read more about Novo Nordisk’s price cuts
Read more about Ozempic and Wegovy price reductions